Copenhagen, Denmark; October 8, 2009, - CMC Biologics A/S announced today the appointment of David Wolton, VP Manufacturing. During his 23 year biotech career, David has held positions with Elan, Wyeth and Lonza.
“We are delighted to add David’s tremendous experience to CMC Biologics. He has a proven track record in managing successful manufacturing teams and will bring new opportunities for production efficiencies”, said Peter Vilby, Chief Operating Officer.
“CMC Biologics continues to attract the highest calibre people in our industry, and David Wolton’s appointment will ensure continued delivery of products to our customers, in the highly demanding regulatory environment of biologicals”, said Mads Laustsen, CEO of CMC Biologics.
About CMC Biologics A/S
CMC Biologics is one of only a handful of leading contract development and manufacturing organizations that provides fully integrated biopharmaceutical development and manufacturing solutions to clients around the world, from its facilities in Europe and the USA. The company has proven expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials and in-market production. CMC’s wide range of integrated services includes cell line development, bioprocess development, formulation and comprehensive analytical testing. Clients can also benefit from CMC’s proprietary CHEF1® expression system for mammalian production. CMC has fully segregated microbial fermentation and mammalian cell culture suites and offers both fed-batch and perfusion production processes. CMC Biologics A/S is located in Copenhagen, Denmark, and CMC ICOS Biologics Inc., is located in Seattle, WA.
Additional information is available on www.cmcbio.com
